- Home
- AMIX vs CERO Comparison
AMIX vs CERO Comparison
Compare AMIX & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- CERO
- Stock Information
- Founded
- AMIX 2014
- CERO 2017
- Country
- AMIX United States
- CERO United States
- Employees
- AMIX N/A
- CERO N/A
- Industry
- AMIX
- CERO
- Sector
- AMIX
- CERO
- Exchange
- AMIX NYSE
- CERO Nasdaq
- Market Cap
- AMIX 3.5M
- CERO 3.5M
- IPO Year
- AMIX N/A
- CERO N/A
- Fundamental
- Price
- AMIX $1.41
- CERO $8.92
- Analyst Decision
- AMIX Strong Buy
- CERO Strong Buy
- Analyst Count
- AMIX 1
- CERO 2
- Target Price
- AMIX $5.00
- CERO $45.00
- AVG Volume (30 Days)
- AMIX 2.4M
- CERO 3.3M
- Earning Date
- AMIX 08-12-2025
- CERO 08-13-2025
- Dividend Yield
- AMIX N/A
- CERO N/A
- EPS Growth
- AMIX N/A
- CERO N/A
- EPS
- AMIX N/A
- CERO N/A
- Revenue
- AMIX N/A
- CERO N/A
- Revenue This Year
- AMIX N/A
- CERO N/A
- Revenue Next Year
- AMIX N/A
- CERO N/A
- P/E Ratio
- AMIX N/A
- CERO N/A
- Revenue Growth
- AMIX N/A
- CERO N/A
- 52 Week Low
- AMIX $1.14
- CERO $6.71
- 52 Week High
- AMIX $42.40
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- AMIX 47.30
- CERO 46.26
- Support Level
- AMIX $1.32
- CERO $9.10
- Resistance Level
- AMIX $1.59
- CERO $9.73
- Average True Range (ATR)
- AMIX 0.20
- CERO 2.67
- MACD
- AMIX 0.03
- CERO 0.04
- Stochastic Oscillator
- AMIX 20.93
- CERO 10.50
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.